Zandi, Souska; Bodaghi, Bahram; Garweg, Justus G. (2018). Review for Disease of the Year: Treatment of Viral Anterior Uveitis: A Perspective. Ocular immunology and inflammation, 26(7), pp. 1135-1142. Informa Healthcare 10.1080/09273948.2018.1498109
Full text not available from this repository.PURPOSE
To define a clinically tailored therapeutic strategy for the treatment of viral anterior uveitis (VAU).
METHODS
A PubMed search spanning the past 5 years was conducted using the MesH-terms "viral anterior uveitis" and "therapy."
RESULTS
The herpes simplex virus (HSV), the varicella zoster virus (VZV), and the cytomegalovirus (CMV) are the predominant pathogens in VAU. Other viruses, including rubella, chikungunya, and zika, have been linked with distinct forms of the disease. Depending on the causative agent and the host immunocompetence, the mainstay treatment for suspected VAU is a combination of topical or systemic antivirals and topical corticosteroids, supplemented with cycloplegics and intraocular-pressure-lowering medication.
CONCLUSIONS
Oral acyclovir, valacyclovir, and famciclovir are the mainstay of treatment for HSV- and VZV-induced infections. Brivudin serves as an alternative in insufficiently responsive cases. CMV-induced infections respond well to valganciclovir. A 3- to 12-month course of prophylactic treatment against recurrences is worth considering.
Item Type: |
Journal Article (Review Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology |
UniBE Contributor: |
Garweg, Justus |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0927-3948 |
Publisher: |
Informa Healthcare |
Language: |
English |
Submitter: |
Sebastian Wolf |
Date Deposited: |
04 Dec 2018 11:31 |
Last Modified: |
05 Dec 2022 15:21 |
Publisher DOI: |
10.1080/09273948.2018.1498109 |
PubMed ID: |
30096015 |
Uncontrolled Keywords: |
Acyclovir antivirals treatment valacyclovir viral anterior uveitis |
URI: |
https://boris.unibe.ch/id/eprint/121830 |